IHS Chemical Week

EnviroTech :: Biotech

Biocon and Optimer Sign API Manufacturing Deal

May 26, 2010 | Deepti Ramesh

Biotechnology company and manufacturing services provider Biocon (Bangalore, India) says it has entered into a long-term supply agreement with biopharmaceutical company Optimer Pharmaceuticals (San Diego, CA) for the commercial manufacturing of the active pharmaceutical ingredient (API) fidaxomicin - Optimer's lead product candidate for the treatment of clostridium difficile infection (CDI). Fidaxomicin is a narrow spectrum antibiotic being developed for the treatment of CDI and Optimer has reported positive top-line results from two Phase 3 trials of...

This information is only available to Chemical Week subscribers.


Forgot your user ID or password?
Click here to have it sent to you.

Not an IHS Chemical Week member yet?

Here's why you should be:

  • 31 issues of Chemical Week magazine in print or digital format
  • Critical daily news and analysis on chemweek.com
  • Free mobile edition 
  • 20+ years of online archives
  • Topical e-newsletters that capture the most impactful events
  • Special issues with a regional or company focus
  • Global Outlook issue

Subscribe now

100% Satisfaction Guarantee
If at any time you are not completely satisfied with IHS Chemical Week, simply notify us and we'll refund the balance of your paid subscription - no problem.

Learn more about group subscriptions and site licenses.


contact us | about us | customer care | privacy policy | sitemap | advertise

ihsCopyright © 2015 IHS, Inc. All rights reserved. Reproduction in whole or in part without permission is prohibited.

North Asia Russia Southeast Asia China India/Pakistan Middle East Eastern Europe Western Europe Central America Canada USA Australia/New Zealand South America Africa